Carfilzomib

K. Martin Kortuem, A. Keith Stewart

Research output: Contribution to journalReview article

114 Scopus citations

Abstract

This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. This review focuses on clinical trial data leading to drug approval and provides advice for treating physicianswhoarenowaccessing this drug for patients.

Original languageEnglish (US)
Pages (from-to)893-897
Number of pages5
JournalBlood
Volume121
Issue number6
DOIs
StatePublished - Feb 7 2013

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Carfilzomib'. Together they form a unique fingerprint.

  • Cite this